| Literature DB >> 25372479 |
Ian Hodgson1, Mary L Plummer2, Sarah N Konopka3, Christopher J Colvin4, Edna Jonas3, Jennifer Albertini5, Anouk Amzel6, Karen P Fogg7.
Abstract
BACKGROUND: Despite progress reducing maternal mortality, HIV-related maternal deaths remain high, accounting, for example, for up to 24 percent of all pregnancy-related deaths in sub-Saharan Africa. Antiretroviral therapy (ART) is effective in improving outcomes among HIV-infected pregnant and postpartum women, yet rates of initiation, adherence, and retention remain low. This systematic literature review synthesized evidence about individual and contextual factors affecting ART use among HIV-infected pregnant and postpartum women.Entities:
Mesh:
Year: 2014 PMID: 25372479 PMCID: PMC4221025 DOI: 10.1371/journal.pone.0111421
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow Diagram for Study Search and Inclusion.
Summary of Key Characteristics of Included Studies.
| Characteristics | Number of studies | |
|
| ||
| Sub-Saharan Africa | 27 | |
| Asia | 1 | |
| Latin America | 2 | |
| Europe/North America | 4 | |
| Middle East | 0 | |
|
| ||
| Rural | 6 | |
| Urban | 12 | |
| Both | 11 | |
| Unclear | 5 | |
|
| ||
| Low (0–5%) | 9 | |
| Moderate (5–15%) | 11 | |
| High (15% or higher) | 14 | |
|
| ||
| Quantitative methods | 16 | |
| Qualitative methods | 12 | |
| Mixed methods | 6 | |
|
| ||
| Yes | 4 | |
| No | 30 | |
Antiretroviral medication regimens in included studies.
| Regimen | Purpose: PMTCT Prophylaxis | Purpose: Treatment for the Mother | Notes |
|
| One intrapartum dose taken at thebeginning of a woman’s labor | N/A | Introduced in 2000, this regimen is no longer recommended by WHO unless as part of combination PMTCT (Option A) |
|
|
|
| |
| (a) Antepartum: Antenatal zidovudine(AZT) twice daily starting as early as14 weeks gestation | Triple antiretroviral medications (ARVs) often combined within a single pill (a “fixed dose combination”) that is taken twice daily, starting as soon asdiagnosed and continued for life | ||
| (b) Intrapartum: at onsent of labor, sdNVP and AZT every 3 hours and lamivudine (3TC) every 12 hours until delivery | |||
| (c) Postpartum: twice daily AZT/3TC for 7 days | |||
|
| Triple ARVs starting as early as 14 weeks gestation and continuedintrapartum and throughchildbirth if not breastfeedingor until 1 week after cessation of breastfeeding | Triple ARVs starting assoon as diagnosed,continued for life | Under WHO’s 2010 PMTCT ARV guidance, countries have the option to choose between two prophylaxis regimens for pregnant women living with HIV: Option A and Option B. |
|
| Triple ARVs starting as soon asdiagnosed, continued for life | Triple ARVs starting assoon as diagnosed,continued for life | Option B+ was conceived and implemented in Malawi in 2011. In April 2012, WHO released a programmatic update in which it urged countries to consider Option B and B+ |
*PMTCT prophylaxis refers to the use of ARV drugs solely for the purpose of reducing the risk of vertical transmission when a woman is not on standard ART for therapeutic reasons.
Summary of ART Enabler and Barrier Findings, by Level and Outcome of Interest.
| Initiation | Adherence | Retention | ||||
| Enabler | Barrier | Enabler | Barrier | Enabler | Barrier | |
|
| • Knowledge of PMTCT and referral process (higher) | • Age (lower) | • Age (higher) | • Age (lower) | • Sufficient knowledge of PMTCT | • Poor knowledge of ART |
| • | • Desire to protect child | • Knowledge of PMTCT (lower) | • Education level (higher) | • Education level (lower) | • Access to cell phone (text reminders/appointments) | • HIV denial |
| • | • Education level (higher) | • Denial of HIV | • Sufficient knowledge of PMTCT | • Rural residency | • Religion | • Scheduling problems |
| • Fear of job loss | • Desire to remain healthy | • HIV denial | • Religion | |||
| • Reluctance to start lifelong treatment | • Desire to protect child | • Concern ART will harm child | ||||
| • Forgetting medication | • Conflict with role as homemaker | |||||
| • Scheduling problems | • Misplacing medication | |||||
| • Feeling too healthy | • Forgetting medication | |||||
| • Away from home | ||||||
| • Lack of food/water/income | ||||||
| • Religion | ||||||
| • Use of drugs/alcohol | ||||||
|
| • Partner involved in care | • Dependence on or permission needed from partner | • Disclosure to partner | • Dependence on or permission needed from partner | • Disclosure to partner | • Dependence on or permission needed from partner |
| • Non-disclosure to partner | • Partner involved in care | • Fear of domestic violence after disclosure | • Partner not involved in care | • Fear of domestic violence after disclosure | ||
| • Partner not involved in care | • Family support | • No family support | ||||
| • No support from family | • Relatives ‘stealing’ ART pills | |||||
|
| • Actual or anticipated stigma | • Disclosure without stigma | • Actual or anticipated stigma | • Actual or anticipated stigma | ||
|
| • Support group participation | • Low attendance at ANC | • Receiving other treatment (e.g., for tuberculosis) or vitamin supplements | • Actual or anticipated breach of confidentiality in health center | • First pregnancy registration | • Late disengagement (within 30 days of delivery) |
| • Treatment support or counseling | • Negative health worker attitudes | • Enrolment in ART pre-delivery | • Payment problems | • Community health worker involvement | • Low or late attendance at ANC | |
| • Encouragement from a traditional birth attendant | • Long queues at health center | • Negative health worker attitudes | • Successful completion of PMTCT pre-delivery | • Negative health worker attitudes | ||
| • Transportation problems | • Long queues at health center | • Enrolment in ART pre-delivery | • Actual or anticipated breach of confidentiality | |||
| • Medications not dispensed correctly | • Long queues at health center | |||||
| • Transportation problems | • Transportation problems | |||||
Strength of Evidence and Generalizability/Transferability of Key Review Findings to High Prevalence Contexts.
| Level of Influence | Key Review Finding | Strength of Evidence Summary | Generalizability/Transferability Summary |
|
| 1a) Socio-demographic factors (i.e., age, educational level, residency) can influence ART initiation, adherence, and retention. |
|
|
| 1b) Level of knowledge about health services, ART, and/or PMTCT can affect ART initiation, adherence, and retention. |
|
| |
| 1c) Women’s fears and perceptions of treatment, and the desire to maintain their roles and status within families, can affect ART initiation, adherence, and retention. |
|
| |
| 1d) Factors in a woman’s daily life can affect ART initiation, adherence, and retention. |
|
| |
| 1e) Beliefs (e.g., religious beliefs, feeling healthy, and having a positive outlook) can affect ART initiation, adherence, and retention. |
|
| |
| 1f) Behavioral factors can be key barriers to ART initiation, adherence, and retention. |
|
| |
|
| 2a) Relationships with partners can have a substantial influence on ART initiation, adherence, and retention. |
|
|
| 2b) Relationships within the family affect ART initiation, adherence, and retention. |
|
| |
|
| 3) Stigma within a community can be a significant barrier to ART initiation, adherence, and retention. |
|
|
|
| 4a) Higher participation in recommended health services leads to increased likelihood of ART initiation, adherence, and retention. |
|
|
| 4b) Logistical problems around access to services can be barriers to ART initiation, adherence, and retention. |
|
| |
| 4c) Interactions with health workers are valued, and affect the quality of access, and likelihood of ART initiation, adherence, and retention. |
|
|